Teva links with Optimata for cancer research
This article was originally published in Scrip
Executive Summary
Teva Pharmaceutical Industries will access novel technology for the virtual modelling of patient/drug interactions through an alliance with fellow Israeli company Optimata. The tie-up will focus on the reprofiling of molecules discontinued by originator companies for potential use in solid tumours. Optimata's virtual patient computer simulation technology allows the modelling of key human physiological processes to help determine optimum treatment, predict interactions and design clinical trials. Teva will make up-front, milestone and royalty payments and has also taken an undisclosed equity stake in Optimata as part of the deal.